Citigroup Inc I Mab Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in I Mab stock. As of the latest transaction made, Citigroup Inc holds 50 shares of IMAB stock, worth $75. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 50 -0.0%

Holding current value

$75

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$1.21 - $1.9 $1,049 - $1,647	-867 Reduced 94.55%	50 $0
Q3 2023 Nov 09, 2023	SELL	$1.18 - $3.06 $27,404 - $71,065	-23,224 Reduced 96.2%	917 $1,000
Q2 2023 Aug 10, 2023	SELL	$2.95 - $3.85 $85,514 - $111,603	-28,988 Reduced 54.56%	24,141 $72,000
Q1 2023 May 11, 2023	SELL	$3.08 - $7.39 $7,392 - $17,736	-2,400 Reduced 4.32%	53,129 $183,000
Q4 2022 Feb 09, 2023	BUY	$3.22 - $4.86 $123,026 - $185,686	38,207 Added 220.57%	55,529 $232,000

Q3 2022 Nov 10, 2022	SELL	$4.01 - $12.34 $282,809 - $870,290	-70,526 Reduced 80.28%	17,322 $69,000
Q2 2022 Aug 10, 2022	BUY	$8.27 - $18.43 $177,035 - $394,531	21,407 Added 32.22%	87,848 $993,000
Q1 2022 May 12, 2022	BUY	$12.54 - $46.93 $555,070 - $2.08 Million	44,264 Added 199.59%	66,441 $1.08 Million
Q4 2021 Feb 10, 2022	BUY	$45.28 - $74.5 $57,052 - $93,870	1,260 Added 6.02%	22,177 $1.05 Million
Q3 2021 Nov 10, 2021	BUY	$57.18 - $84.43 $1.2 Million - $1.77 Million	20,917 New	20,917 $1.52 Million

Others Institutions Holding IMAB

# of Institutions

Shares Held

16M

Call Options Held

11.9K

Put Options Held

3.5K

Hhlr Advisors, Ltd. Grand Cayman, E9

6.91M
Shares

$10.4 Million
0.29% of portfolio
Decheng Capital Management Iii (Cayman), LLC

4.17M
Shares

$6.25 Million
3.04% of portfolio
David A. Siegel Two Sigma Advisers, LP | New York, Ny

617K
Shares

$925,650
0.0% of portfolio
Two Sigma Investments, LP New York, NY

576K
Shares

$863,370
0.0% of portfolio
Temasek Holdings (Private) LTD Singapore, U0

567K
Shares

$849,975
0.01% of portfolio

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $125M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account